NYSEAMERICAN:ELMD - Electromed Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Electromed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Electromed.

Electromed is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Electromed.

Electromed, Inc. (NYSEAMERICAN:ELMD) issued its quarterly earnings data on Tuesday, February, 11th. The medical equipment provider reported $0.14 EPS for the quarter, topping the consensus estimate of $0.04 by $0.10. The medical equipment provider earned $8.55 million during the quarter. View Electromed's earnings history.

1 Wall Street analysts have issued 12-month price objectives for Electromed's stock. Their forecasts range from $12.00 to $12.00. On average, they expect Electromed's stock price to reach $12.00 in the next year. This suggests a possible upside of 6.8% from the stock's current price. View analysts' price targets for Electromed.

News stories about ELMD stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Electromed earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutElectromed.

Electromed saw a increase in short interest in March. As of March 13th, there was short interest totaling 49,300 shares, an increase of 142.9% from the February 27th total of 20,300 shares. Based on an average daily volume of 78,400 shares, the short-interest ratio is presently 0.6 days. Approximately 0.7% of the company's shares are short sold. View Electromed's Current Options Chain.

Some companies that are related to Electromed include Zynex (ZYXI), Creo Medical Group (CREO), Hamilton Thorne (HTL), Medica Group (MGP), Cyclopharm (CYC), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), MRI Interventions (MRIC), REVA Medical (RVA), Advanced Oncotherapy (AVO), Patient Home Monitoring (PTQ), Protech Home Medical (PHM), Oventus Medical (OVN), Kromek Group (KMK), Resonance Health (RHT) and Respiri (RSH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Electromed investors own include NovaBay Pharmaceuticals (NBY), TransEnterix (TRXC), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), TherapeuticsMD (TXMD), AbbVie (ABBV), Agenus (AGEN), Akari Therapeutics (AKTX) and Athersys (ATHX).

Electromed trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ELMD."

Shares of ELMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ELMD stock can currently be purchased for approximately $11.24.

Electromed has a market capitalization of $95.29 million. Electromed employs 132 workers across the globe. View additional information about Electromed.

The official website for Electromed is http://smartvest.com/.

Electromed's mailing address is 500 6th Ave NW, NEW PRAGUE, MN 56071-1134, United States. The medical equipment provider can be reached via phone at +1-952-7589299.